Krystal Biotech, Inc.
KRYS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711279
In the last 90 days, Krystal Biotech, Inc. insiders filed 0 open-market purchases and 3 sales; 422 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Krystal Biotech, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- 0 vs. Q1 2021
- Shares held
- 16.4M
- −73.7K (−0.4%) vs. Q1 2021
- Total value
- $1.12B
- −$153.3M (−12.1%) vs. Q1 2021
- New holders
- 13
- 54 more added
- Sold out
- 13
- 30 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KRYS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 422 | $11.1B |
| Q1 2026 | 368 | $7.32B |
| Q4 2025 | 334 | $7.01B |
| Q3 2025 | 284 | $4.94B |
| Q2 2025 | 275 | $3.80B |
| Q1 2025 | 299 | $4.98B |
| Q4 2024 | 264 | $4.35B |
| Q3 2024 | 283 | $5.15B |
| Q2 2024 | 245 | $5.24B |
| Q1 2024 | 234 | $4.49B |
| Q4 2023 | 194 | $3.03B |
| Q3 2023 | 188 | $2.76B |
| Q2 2023 | 183 | $2.71B |
| Q1 2023 | 160 | $1.68B |
| Q4 2022 | 154 | $1.66B |
| Q3 2022 | 148 | $1.45B |
| Q2 2022 | 137 | $1.36B |
| Q1 2022 | 135 | $1.37B |
| Q4 2021 | 140 | $1.35B |
| Q3 2021 | 113 | $850.7M |
| Q2 2021 | 113 | $1.12B |
| Q1 2021 | 113 | $1.27B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Krystal Biotech, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 410,881 | $27.9M | 0.00% | +26,603+6.9% | Added |
| Artal Group S.A. | 500,000 | $34.0M | 0.77% | 00.0% | Unchanged |
| First Light Asset Management, LLC | 526,650 | $35.8M | 2.15% | +35,139+7.1% | Added |
| Pictet Asset Management Ltd | 557,480 | $37.9M | 0.04% | +140,600+33.7% | Added |
| Baker Bros. Advisors LP | 607,735 | $41.3M | 0.18% | −152,677−20.1% | Reduced |
| State Street Corp | 712,997 | $48.5M | 0.00% | +54,039+8.2% | Added |
| Credit Suisse AG | 766,325 | $52.1M | 0.04% | −13,075−1.7% | Reduced |
| Frazier Management LLC | 787,876 | $53.6M | 4.94% | −107,124−12.0% | Reduced |
| Vanguard Group Inc | 846,355 | $57.6M | 0.00% | +15,944+1.9% | Added |
| Lord, Abbett & Co. LLC | 1,191,580 | $81.0M | 0.20% | −194,063−14.0% | Reduced |
| BlackRock Inc. | 1,532,346 | $104.2M | 0.00% | +51,718+3.5% | Added |
| FMR LLC | 1,767,917 | $120.2M | 0.01% | +426,020+31.7% | Added |
| Redmile Group, LLC | 2,072,132 | $140.9M | 2.09% | +12,000+0.6% | Added |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −29,836−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −27,500−100.0% | Sold out |
| Aviva PLC | 0 | $0 | 0.00% | −17,198−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −12,640−100.0% | Sold out |
| Gilder Gagnon Howe & Co LLC | 0 | $0 | 0.00% | −6,769−100.0% | Sold out |
| Windsor Creek Advisors, LLC | 0 | $0 | 0.00% | −5,500−100.0% | Sold out |
| Ritholtz Wealth Management | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −2,776−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −602−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −556−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −491−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −48−100.0% | Sold out |